Biologics Market Transparency Act of 2022

Senate Bill 4302 - Biologics Market Transparency Act of 2022: Overview, Status, and Impact

Hozzl · 2022-12-29T16:48:34Z

Explore the details of Senate Bill 4302 Biologics Market Transparency Act of 2022 currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

12/29/2022, 4:48 PM

Congressional Summary of S 4302

Biologics Market Transparency Act of 2022

This bill requires biologics manufacturers to notify the Food and Drug Administration in advance of withdrawing a product from sale.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill S 4302

Bill S 4302 is currently in the status of Bill Introduced since May 25, 2022. Bill S 4302 was introduced during Congress 117 and was introduced to the Senate on May 25, 2022. Bill S 4302's most recent activity was Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S2709) as of May 25, 2022

Bipartisan Support of Bill S 4302

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill S 4302

Primary Policy Focus

Health

Alternate Title(s) of Bill S 4302

Biologics Market Transparency Act of 2022

A bill to amend the Federal Food, Drug, and Cosmetic Act to require prompt reports of marketing status by holders of approved applications for biological products, and for other purposes.